Literature DB >> 24847650

Resistance to Raf inhibition in cancer.

H Eirik Haarberg, Keiran S M Smalley.   

Abstract

The use of small molecule BRAF inhibitors has revolutionized the treatment of advanced melanoma. Despite this, resistance is commonplace and associated with a median progression-free survival of >5 months. Major resistance mechanisms include reactivation of the MAPK pathway and increased PI3K/AKT signaling. Here we review some of the combination therapeutic strategies currently undergoing evaluation for the management of acquired drug resistance in melanoma.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24847650      PMCID： PMC4031441          DOI： 10.1016/j.ddtec.2013.12.004

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN： 1740-6749


  37 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Authors:  Inna V Fedorenko; Kim H T Paraiso; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2011-05-25       Impact factor: 5.858

3.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

4.  Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.

Authors:  James G Greger; Stephen D Eastman; Vivian Zhang; Maureen R Bleam; Ashley M Hughes; Kimberly N Smitheman; Scott H Dickerson; Sylvie G Laquerre; Li Liu; Tona M Gilmer
Journal:  Mol Cancer Ther       Date:  2012-03-02       Impact factor: 6.261

5.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Authors:  Jessie Villanueva; Adina Vultur; John T Lee; Rajasekharan Somasundaram; Mizuho Fukunaga-Kalabis; Angela K Cipolla; Bradley Wubbenhorst; Xiaowei Xu; Phyllis A Gimotty; Damien Kee; Ademi E Santiago-Walker; Richard Letrero; Kurt D'Andrea; Anitha Pushparajan; James E Hayden; Kimberly Dahlman Brown; Sylvie Laquerre; Grant A McArthur; Jeffrey A Sosman; Katherine L Nathanson; Meenhard Herlyn
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

6.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors:  Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

7.  The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.

Authors:  Kim H T Paraiso; H Eirik Haarberg; Elizabeth Wood; Vito W Rebecca; Y Ann Chen; Yun Xiang; Antoni Ribas; Roger S Lo; Jeffrey S Weber; Vernon K Sondak; Jobin K John; Amod A Sarnaik; John M Koomen; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2012-02-20       Impact factor: 12.531

8.  Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.

Authors:  Hubing Shi; Gatien Moriceau; Xiangju Kong; Richard C Koya; Ramin Nazarian; Gulietta M Pupo; Antonella Bacchiocchi; Kimberly B Dahlman; Bartosz Chmielowski; Jeffrey A Sosman; Ruth Halaban; Richard F Kefford; Georgina V Long; Antoni Ribas; Roger S Lo
Journal:  Cancer Discov       Date:  2012-04-01       Impact factor: 39.397

9.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

10.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors:  Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962
View more
  12 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

2.  Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.

Authors:  Raghavendra Gowda; Gregory Kardos; Arati Sharma; Sanjay Singh; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2016-12-21       Impact factor: 6.261

3.  Targeting RAS-mutant cancers: is ERK the key?

Authors:  Meagan B Ryan; Channing J Der; Andrea Wang-Gillam; Adrienne D Cox
Journal:  Trends Cancer       Date:  2015-11-01

4.  Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition.

Authors:  Andrew P Trotta; Jesse D Gelles; Madhavika N Serasinghe; Patrick Loi; Jack L Arbiser; Jerry E Chipuk
Journal:  J Biol Chem       Date:  2017-05-25       Impact factor: 5.157

5.  The role of palbociclib in thyroid carcinoma with BRAF mutation.

Authors:  Nikolaos Tsoukalas; Konstantinos Tsapakidis; Krystallenia I Alexandraki
Journal:  Gland Surg       Date:  2018-08

Review 6.  The Anti-cancer Effect of Olea europaea L. Products: a Review.

Authors:  Chrystalla Antoniou; Jonathon Hull
Journal:  Curr Nutr Rep       Date:  2021-03-08

7.  HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells.

Authors:  Soon-Duck Ha; Naomi Lewin; Shawn S C Li; Sung-Ouk Kim
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

8.  Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.

Authors:  You-Take Oh; Jiusheng Deng; Ping Yue; Shi-Yong Sun
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

9.  Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.

Authors:  Elyse K Hanly; Neha Y Tuli; Robert B Bednarczyk; Robert Suriano; Jan Geliebter; Augustine L Moscatello; Zbigniew Darzynkiewicz; Raj K Tiwari
Journal:  Oncotarget       Date:  2016-02-23

Review 10.  Targeted Therapies for Pancreatic Cancer.

Authors:  Idoroenyi Amanam; Vincent Chung
Journal:  Cancers (Basel)       Date:  2018-01-29       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.